期刊
FEBS JOURNAL
卷 288, 期 13, 页码 3962-3972出版社
WILEY
DOI: 10.1111/febs.15599
关键词
aryl hydrocarbon receptor; cell therapy; mesenchymal stromal cells
资金
- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases award [R01DK109508]
MSCs are promising investigational cellular therapeutics for tissue injury regeneration and immune-mediated diseases, with the transcription factor AhR playing a crucial role in inflammation, immunomodulation, and plasticity of these cells.
Mesenchymal stromal cells (MSCs) are nonhematopoietic cells that have been clinically explored as investigational cellular therapeutics for tissue injury regeneration and immune-mediated diseases. Their pharmaceutical properties arise from activation of endogenous receptors and transcription factors leading to a paracrine effect which mirror the biology of progenitors from which they arise. The aryl hydrocarbon receptor (AhR) is a transcription factor that has been extensively studied as an environmental sensor for xenobiotics, but recent findings suggest it can modulate immunological functions. Both genetic and pharmacological investigations revealed that MSCs express AhR and that it plays roles in inflammation, immunomodulation, and mesodermal plasticity of endogenous MSCs. Further, AhR has been shown to interact with key signaling cascades associated with these conditions. Therefore, AhR has potential to be an attractive target in both endogenous and culture-adapted MSCs for novel therapeutics to treat inflammation and other age-related disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据